Clinical trial
Oxaliplatin in Unresectable Hepatocellular Carcinoma
NCT00280618 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00280618 |
|---|---|
| Title | Oxaliplatin in Unresectable Hepatocellular Carcinoma |
| Official title | Phase II Study of Eloxatin + 5-Fluorouracil/Leucovorin in Patients With Unresectable Hepatocellular Carcinoma |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Drug |
| Interventions | Oxaliplatin |
| Start date | Jul 1, 2004 |
| Primary completion | Nov 1, 2006 |
| First posted | Jan 23, 2006 |
| Last update posted | Sep 15, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: